Inventor · disambiguated record
Brandon Reid Rosen
Also filed as: ROSEN BRANDON · ROSEN BRANDON REID
19 granted patents·4 pending applications·81 citations·filing 2017–2024
93Inventor score
Files withARCUS BIOSCIENCES INC23
Top patents by PatentIndex Score
23 records- 0198US11001603B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2020·Granted May 11, 2021·13 cites·1 claims
- 0296US10239912B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2017·Granted Mar 26, 2019·23 cites·47 claims
- 0395US11667662B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2021·Granted Jun 6, 2023·4 cites·9 claims
- 0495US10981944B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2019·Granted Apr 20, 2021·11 cites·20 claims
- 0594US12168023B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Granted Dec 17, 2024·1 cites·24 claims
- 0694US11787762B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alphaARCUS BIOSCIENCES INC·Filed 2022·Granted Oct 17, 2023·2 cites·26 claims
- 0793US11407712B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2αARCUS BIOSCIENCES INC·Filed 2021·Granted Aug 9, 2022·3 cites·15 claims
- 0892US12145901B1Process for preparing tetralin compoundsARCUS BIOSCIENCES INC·Filed 2022·Granted Nov 19, 2024·2 cites·25 claims
- 0992US10399962B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2018·Granted Sep 3, 2019·13 cites·25 claims
- 1088US12195447B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2021·Granted Jan 14, 2025·1 cites·2 claims
- 1187US11072597B2Azolopyrimidine for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2019·Granted Jul 27, 2021·3 cites·14 claims
- 1286US12459967B2Modulators of 5′-nucleotidase, ecto and the use thereofARCUS BIOSCIENCES INC·Filed 2023·Granted Nov 4, 2025·0 cites·11 claims
- 1386US12103907B2Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alphaARCUS BIOSCIENCES INC·Filed 2023·Granted Oct 1, 2024·0 cites·1 claims
- 1485US11058704B2Inhibitors of adenosine 5′-nucleotidaseARCUS BIOSCIENCES INC·Filed 2017·Granted Jul 13, 2021·4 cites·25 claims
- 1583US2025319113A1Inhibitors of adenosine 5'-nucleotidaseARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1682US2025214930A1Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alphaARCUS BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 1779US11045472B2Quinazoline-pyridine derivatives for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2018·Granted Jun 29, 2021·1 cites·20 claims
- 1860US12071411B2Inhibitors of HIF-2α and methods of use thereofARCUS BIOSCIENCES INC·Filed 2022·Granted Aug 27, 2024·0 cites·31 claims
- 1951US2022235031A1Processes for preparing aminopyrimidine compoundsARCUS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 2051US2023024438A1Inhibitors of hif-2alphaARCUS BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 2150US12226425B2Inhibitors of ARG1 and/or ARG2ARCUS BIOSCIENCES INC·Filed 2019·Granted Feb 18, 2025·0 cites·11 claims
- 2248US12064433B2Pyridone A2R antagonistsARCUS BIOSCIENCES INC·Filed 2019·Granted Aug 20, 2024·0 cites·25 claims
- 2344US11220492B2Quinazoline-pyrazole derivatives for the treatment of cancer-related disordersARCUS BIOSCIENCES INC·Filed 2018·Granted Jan 11, 2022·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when Brandon Reid Rosen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →